<DOC>
	<DOCNO>NCT00001830</DOCNO>
	<brief_summary>Allogeneic peripheral blood stem cell transplantation ( PBSCT ) primarily limit graft-versus-host disease ( GVHD ) . In murine model , demonstrate donor CD4+ T cell Th1 cytokine phenotype ( defined secretion IL-2 IFN-gamma ) mediate GVHD . In contrast , donor CD4+ T cell Th2 phenotype ( defined secretion IL-4 , IL-5 , IL-10 ) generate GVHD , abrogate Th-1-mediated GVHD . Importantly , demonstrate enrichment murine allograft Th2 cell reduce GVHD without impair ability donor T cell prevent graft rejection . These study indicate administration Th2 cell allogeneic transplantation represent strategy achieve alloengraftment reduce GVHD . In addition GVHD , allogeneic PBSCT limit toxicity associate conventional myeloablative preparative regimen . Such regimen , typically utilize total body irradiation ( TBI ) high-dose chemotherapy , consider essential prevention graft rejection . However , recent clinical study show non-myeloablative dos fludarabine-based chemotherapy result alloengraftment . In murine model , demonstrate severe host T cell depletion induce combination fludarabine cytoxan prevent even fully-MHC mismatch marrow graft rejection . Although non-myeloablative regimen may reduce regimen-related toxicity , transplant associate 30 40 % incidence severe acute GVHD similar rate observe myeloablative regimen . Because non-myeloablative regimen appear associate reduced regimen-related toxicity , elect conduct phase I study Th2 cell set immunoablative ( non-myeloablative ) preparative regimen . Patients leukemia clinical remission , patient refractory lymphoid malignancy candidate HLA-matched allogeneic PBSCT protocol . Patients receive novel induction regimen ( fludarabine EPOCH ) transplant preparative regimen ( fludarabine cytoxan ) design maximally deplete host immune T cell capable mediate graft rejection . After induction preparative regimen chemotherapy , patient receive unmanipulated , G-CSF mobilize PBSC graft . In initial six patient receive transplant procedure NCI , graft rejection successfully prevent ( 100 % donor chimerism day 30 post-transplant ) . Importantly , GVHD observe six patient , three six patient develop severe GVHD ( grade III ) . Given regimen successfully achieves donor engraftment , associate significant GVHD , transplant regimen represent excellent clinical set evaluation Th2 cell . Using non-myeloablative allogeneic PBSCT approach , perform Phase I study evaluate safety feasibility administer donor Th2 cell day 1 post-transplant . Prior transplantation , donor CD4+ T cell stimulate vitro use culture condition support generation donor CD4 cell Th2 cytokine profile . If Phase I study demonstrate Th2 cell administration safe feasible , Phase III study perform evaluate whether Th2 cell administration reduce incidence severity GVHD . Successful implementation Th2 strategy greatly reduce morbidity mortality associate allogeneic PBSCT , may also represent approach stem cell transplantation patient lack HLA-matched donor .</brief_summary>
	<brief_title>Donor Th2 Cells Prevent Graft-Versus-Host Disease Bone Marrow Transplants</brief_title>
	<detailed_description>Allogeneic peripheral blood stem cell transplantation ( PBSCT ) primarily limit graft-versus-host disease ( GVHD ) . In murine model , find donor CD4+ Th1 cell ( secretion IL-2 IFN-Gamma ) mediate GVHD . In contrast , donor Th2 cell ( secretion IL-4 IL-10 ) generate GVHD , abrogate Th1-mediated GVHD . We also find murine allograft enrich Th2 cell reduce GVHD without impair ability donor T cell prevent graft rejection . These study indicate donor Th2 cell may new approach reduce GVHD . In addition GVHD , allogeneic PBSCT limit toxicity associate conventional myeloablative preparative regimen . Although non-myeloablative regimen may reduce regimen-related toxicity , transplant associate 30 40 % incidence severe acute GVHD ( similar rate observe myeloablative regimen ) . Because non-myeloablative regimen appear reduce regimen-related toxicity , conduct pilot study Th2 cell set immunoablative ( non-myeloablative ) preparative regimen . In protocol , patient lymphoid hematologic malignancy receive induction therapy ( fludarabine EPOCH ) transplant chemotherapy ( fludarabine cytoxan ) deplete host T cell mediate graft rejection . In initial NCI cohort receive HLA-matched sibling , G-CSF mobilize PBSCT protocol ( n=19 ) , graft rejection prevent case , recipient 100 % donor chimerism day 28 post-SCT . With reduced intensity regimen , GVHD remain significant complication , 6/19 recipient grade II 6/19 recipient grade III acute GVHD . Importantly , potent graft-versus-tumor response observe , 9/19 patient remain complete remission median 17 month post-SCT . Given allogeneic SCT regimen achieve engraftment durable anti-tumor response , yet associate GVHD , protocol represent appropriate set evaluation donor Th2 cell . Initial patient receive Th2 cell phase I manner . Three patient receive 5 x 10 ( 6 ) Th2/kg , six patient receive 2.5 x 10 ( 7 ) Th2/kg , six patient receive 1.25 x 10 ( 8 ) Th2/kg . The high dose Th2 cell result acceptable toxicity profile ( 1/6 serious adverse event ) favorable rate acute GVHD ( 2/6 case grade II great acute GVHD ) select phase II study arm . Eighteen patient treat allogeneic SCT Th2 cell phase II study arm . In event Th2 recipient reduce GVHD , clinical trial involve Th2 cell warrant .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>INCLUSION CRITERIA Patient : Patients lymphoid malignancy leukemia ( include myelodysplasia ) candidate study . The following diagnosis age consider : Chronic Lymphocytic Leukemia , Age 1875 1 . Relapse Postfludarabine , 2 . NonCR Salvage Regimen Hodgkin 's NonHodgkin 's Lymphoma ( type , include Mantle Cell Lymphoma ) , Age 1875 1 . Primary Treatment Failure , 2 . Relapse AutoSCT , 3 . NonCR Salvage Regimen Multiple Myeloma , Age 1875 1 . Primary Treatment Failure , 2 . Relapse AutoSCT , 3 . NonCR Salvage Regimen Acute Myelogenous Leukemia , Age 1875 1 . In CR # 1 , 2 , 3 2 . Any Relapse le 10 % blast ( marrow blood ) Acute Lymphocytic Leukemia , Age 1875 1 . In Complete Remission # 2 2 . In Complete Remission # 3 3 . Any Relapse le 10 % blast ( marrow blood ) . Myelodysplastic Syndrome , Age 1875 1 . RAEB 2 . RAEBT ( blast less 10 % marrow blood induction chemotherapy ) Chronic Myelogenous Leukemia , Age 1875 1 . Chronic Phase CML 2 . Accelerated Phase CML Patient age least 18 great 75 year age . Availability 6/6 antigen ( A , B , DR ) HLAmatched sibling donor . Karnofsky performance status great equal 70 % . Life expectancy great 3 month . Serum bilirubin less 2.5 mg/dL , serum ALT AST value less equal 2.5 time upper limit normal . Values level may accept , discretion PI study chairman , elevation think due tumor involvement lymphoid malignancy . If value normalize induction chemotherapy , patient eligible transplant phase protocol , thus take study . Creatinine clearance great equal 60 ml/min serum creatinine less equal 1.5 mg/dl . DLCO great 50 % predict . Left ventricular ejection fraction great equal 45 % MUGA ECHO . Ability give inform consent . Durable power attorney form complete . INCLUSION CRITERIA Donor : Must sibling , match recipient 6/6 HLA locus ( A , B , DR ) . Adequate venous access peripheral apheresis , consent use temporary central venous catheter apheresis . Must least 12 year age . Ability give inform consent . For donor 18 year age , assent form must complete . EXCLUSION CRITERIA Patient : Infection respond antimicrobial therapy . Active CNS involvement tumor . HIV positive ( due unacceptable risk allogeneic transplantation ) . Hepatitis B C surface antigen positive . Lactating pregnant female ( due risk fetus newborn ) . History psychiatric disorder may compromise compliance transplant protocol , allow appropriate inform consent ( determine principal investigator study chairman ) . EXCLUSION CRITERIA Donor : History psychiatric disorder may compromise compliance transplant protocol , allow appropriate inform consent . History hypertension control medication , stroke , severe heart disease . Individuals symptomatic angina , history coronary artery bypass graft angioplasty consider severe heart disease , thus eligible donor . Anemia ( Hb le 11 gm/dl ) thrombocytopenia ( PLT le 100,000 per ul ) . Lactating pregnant female . HIV positive . Hepatitis B C antigen positive .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 19, 2015</verification_date>
	<keyword>Bone Marrow Transplantation</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Graft v . Host Disease</keyword>
	<keyword>Lymphoid Malignancy</keyword>
	<keyword>Leukemia</keyword>
</DOC>